2023
Biological treatment for bullous pemphigoid
Oren-Shabtai M, Mimouni D, Nosrati A, Atzmony L, Kaplan B, Barzilai A, Baum S. Biological treatment for bullous pemphigoid. Frontiers In Immunology 2023, 14: 1157250. PMID: 37180101, PMCID: PMC10172582, DOI: 10.3389/fimmu.2023.1157250.Peer-Reviewed Original ResearchMeSH KeywordsAdultHumansImmunosuppressive AgentsOmalizumabPemphigoid, BullousRituximabSkin Diseases, VesiculobullousConceptsBullous pemphigoidImmunosuppressive therapyPatients treated with rituximabLong-term corticosteroid useAdjuvant immunosuppressive therapyConventional immunosuppressive therapySteroid-sparing agentsAutoimmune subepidermal bullous diseaseFirst-line treatmentPrevious treatment failuresSeries of patientsFollow-up periodFollow-up visitSignificant side effectsNo adverse eventsSubepidermal bullous diseasesBP durationRecalcitrant BPRituximab coursesSystemic corticosteroidsClinical responseTreatment failureCorticosteroid useImmunobiological therapyBiologic therapy
2022
Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series
Ahearn EL, Belzer A, Cohen SR, Leventhal JS, Deverapalli SC. Psoriasiform and lichenoid eruptions as a potential harbinger of bullous dermatoses in the setting of immune checkpoint inhibitors: a case series. International Journal Of Dermatology 2022, 62: e411-e414. PMID: 36271737, DOI: 10.1111/ijd.16464.Peer-Reviewed Original Research
2018
Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapy
2017
A 71‐year‐old man with a hemorrhagic vesicular eruption
Hamilton CE, King BA, Cowper SE, Hochster H, Leventhal JS. A 71‐year‐old man with a hemorrhagic vesicular eruption. International Journal Of Dermatology 2017, 57: 147-148. PMID: 29057466, DOI: 10.1111/ijd.13793.Peer-Reviewed Case Reports and Technical NotesAgedAnticoagulantsDrug EruptionsEnoxaparinHemorrhageHumansMaleSkin Diseases, VesiculobullousVenous Thrombosis
1994
Immunofluorescent analysis of the basement membrane zone in lichen planus suggests destruction of the lamina lucida in bullous lesions
Smoller B, Glusac E. Immunofluorescent analysis of the basement membrane zone in lichen planus suggests destruction of the lamina lucida in bullous lesions. Journal Of Cutaneous Pathology 1994, 21: 123-128. PMID: 8040461, DOI: 10.1111/j.1600-0560.1994.tb00246.x.Peer-Reviewed Original ResearchConceptsBasement membrane zoneLichen planusMembrane zoneLymphocytic infiltrateBullous lesionsBullous pemphigoid antigenIntense lymphocytic infiltrateLamina lucida regionPemphigoid antigenNormal staining patternInflammatory dermatosesDermal-epidermal junctionFocal decreasePlanusType IV collagenNormal skinLesionsStaining patternEpidermal junctionImmunofluorescent analysisType VIIInfiltratesIV collagenLamina lucidaAntigen
1990
Figurate and Bullous Eruption in Association With Breast Carcinoma
Watsky K, Orlow S, Bolognia J. Figurate and Bullous Eruption in Association With Breast Carcinoma. JAMA Dermatology 1990, 126: 649-652. PMID: 2185696, DOI: 10.1001/archderm.1990.01670290093016.Peer-Reviewed Case Reports and Technical NotesMeSH KeywordsAgedBreast NeoplasmsCombined Modality TherapyErythemaFemaleHumansMethotrexatePrednisoneSkin Diseases, VesiculobullousConceptsOral administrationHigh-dose oral administrationIntraductal mammary carcinomaMinimal inflammatory infiltrateLower lamina lucidaType of lesionPrednisone therapyCutaneous eruptionBullous eruptionInflammatory infiltrateImmune depositsSubepidermal blistersBreast carcinomaLinear depositionMammary carcinomaDirect immunofluorescenceRadiation therapyDermoepidermal junctionDistal extremitiesFurther evaluationIndirect immunofluorescenceLesionsCarcinomaTherapyLamina lucida
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply